At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 23, 2026 at 16:05 ET
Sutro Biopharma reported its 2025 financial results, highlighted by a 65% year-over-year increase in revenue to $102.5 million, primarily from its Astellas and Ipsen collaborations, while significantly reducing R&D and G&A expenses. The company also announced clinical progress across its ADC pipeline, including dosing in a Phase 1 trial for STRO-004 and advancement of its dual-payload programs, supported by a $110 million capital raise extending its cash runway into Q2 2028.
- Revenue increased 65% YoY to $102.5 million in 2025, up from $62.0 million in 2024, driven by collaboration income from Astellas and Ipsen.
- Total operating expenses dropped from $300.5 million in 2024 to $260.9 million in 2025, with R&D spending down 34% despite ongoing clinical development.
- Cash, cash equivalents, and marketable securities totaled $141.4 million as of December 31, 2025, and a $110 million equity raise extended the cash runway into at least Q2 2028.
- STRO-004 Phase 1 trial completed dosing in three cohorts, with initial clinical data expected mid-2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access